Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravesical Gemcitabine + Docetaxel in NMIBC
NCT05644041Phase 2Active, not recruiting
- Sponsor
- University of Arizona
- Start
- Mar 2023
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, docetaxel in non-muscle-invasive bladder cancer (NMIBC), sponsored by University of Arizona. Started Mar 2023; status: active, not recruiting.
02
Drugs
gemcitabinedocetaxel
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT05644041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05644041.